Market Pulse · Daily Scan

Daily Market Pulse

Aug 31, 2026 · sentiment/flow window ≈ 48h

Pre-marketnot publishedPost-market

TLDR;

A regime handoff, executed over two sessions. For the whole of the prior window the tape was driven by what companies reported; across Aug 31 and Sep 1 it was driven by oil and the long end of the bond market, and almost nothing else mattered. The mechanism was war. US Central Command confirmed a strike on two rocket launchers on Iran's Larak Island over the weekend - the first publicly acknowledged US strike on Iranian positions since late July - with Iranian state media reporting retaliation against US bases in Jordan. Brent closed back above $90 on Aug 31. On Monday night two oil tankers, one Saudi and one South Korean-owned, were hit by projectiles leaving the Strait of Hormuz; the US struck Iranian Revolutionary Guard targets on Tuesday; WTI settled at $90.22, up 5.20%, and Brent at $94.65. Iran threatened to halt Gulf oil exports entirely if pressure continues. The second mechanism was rates, and it was global: the US 10-year reached 4.75%, its highest since January 15 2025; the 30-year settled at 5.243% and has now spent 55 days above 5% this year, the most in any year since 2006; Japan's 10-year briefly touched 3% for the first time in thirty years. September rate-HIKE probability sat at 57.5% on CME FedWatch. The result was a textbook duration selloff dressed as a geopolitical one: the Nasdaq fell 1.03% against the S&P's 0.71%, low-volatility fell 0.2% against high-beta's 2.1%, energy names printed 52-week highs while Nike hit a twenty-year low and Wynn, Las Vegas Sands, VICI and Carnival all hit 52-week lows. The clearest single lesson concerns what this pipeline scored a week ago. The 2026-08-28 artifact's central finding was an AI-software re-rate - Salesforce +22.5%, Okta +28%, CrowdStrike +20.5% - and its registered test was whether Palo Alto's Sep 1 print would confirm it. Within two sessions CrowdStrike gave back 6.9%, Palo Alto fell 5.25% INTO its own print, and the entire question was subordinated to the price of crude. The re-rate may still be real; it stopped being what the market was trading. The most strategically consequential corporate action of the window was consistent with that shift and easy to miss: SLB, the largest oilfield services company in the world, used an oil-shock session to announce a roughly $4.1 billion acquisition of thermal-management business Kelvion, buying its way into the AI power-and-cooling supply chain. Breadth: Negative and narrowing across both sessions, with a clean factor signature. Aug 31: S&P -0.33%, Nasdaq -0.12%, Dow -0.70% with CNBC naming Goldman Sachs and Alphabet as the specific drags - a session in which the two largest single-stock moves in the entire window (EIX -23.07%, PCG -19.13%) came from a state legislature rather than from earnings or macro. Sep 1: damage concentrated hard in growth. The Nasdaq's 1.03% decline ran roughly 1.5x the S&P's 0.71% and the Russell 2000 fell 1.23% to 2,920.13, so the growth and small-cap ends underperformed simultaneously - the rate view expressed at both ends of the risk spectrum at once. The cleanest single breadth statistic is the value-versus-growth spread: SPLV -0.20% against SPHB -2.12%, a 192-basis-point gap in one session. Twelve S&P constituents made 52-week lows against seven 52-week highs, the highs in energy and healthcare and the lows in travel, leisure and consumer. For context that this was a change of regime rather than a crash: all three indexes still closed August higher, the Nasdaq up roughly 3.9% on the month and the Dow logging a fifth consecutive monthly advance, and year to date the Nasdaq is up about 12.3%, the S&P 11.5% and the Dow 9.8%..

A · Daily Pulse

What moved — and why

▲ Rising — dailycomposite

#	Ticker	Move	Driver	Score
1	MRNA	—	The largest confirmed gain of the window and the only ranked riser whose move had nothing to do with oil or rates. Moderna rose 9.93% on Sep 1 on analyst upgrades following late-stage results for a melanoma cancer vaccine developed JOINTLY WITH MERCK, extending an August in which it rose roughly 152% to finish as the month's best-performing security. The 52-week range of $22.28 to $176.66 is the widest in this artifact. Two things matter beyond the magnitude. It rose on a session when the Nasdaq fell 1.03%, so idiosyncratic biotech news still clears a macro tape. And because the vaccine is a Merck collaboration, it is direct evidence against this book's own Track B downside thesis on MRK (downside rank 6), which rests on Merck having no credible second franchise. MAGNITUDE CONFLICT, flagged not averaged: Motley Fool close-basis (published 17:02 ET) gives +9.93%; a ChartMill screen one hour before the close gives +7.05% at $150.24; CNBC's MIDDAY block gives 'gained 5%'. All three are consistent with a stock climbing through the session; the close-basis figure is used.	76
2	AAPL	—	The most awkward entry in the artifact, deliberately so: Apple is simultaneously Track A rising rank 2 and Track B downside rank 3, and the event that produced the gain is the exact event the Track B entry flagged IN ADVANCE as a risk. Tim Cook moved to Executive Chair on Sep 1 with hardware chief John Ternus taking over as CEO of a $4.6 trillion company, and the stock rose 2.61% on a session when the Nasdaq fell 1.03% and the 10-year hit its highest since January 2025. The 2026-08-28 artifact named this precisely - 'a plausible narrative reset with no fundamental content' - and that is what happened. A leadership handover is not an earnings revision; nothing about the memory-supply constraint or the 9-11% revenue guide changed. Recording the gain here and cutting the Track B sentiment leg is the honest treatment of a correct thesis meeting an adverse catalyst. Ranked second on a modest 2.61% because the catalyst is unambiguous, dated and verifiable. ↔ deep-dive	71
3	SLB	—	Initially read as oilfield-services strength on the crude spike; it is not, and the correction matters. On Aug 31 SLB announced an agreement to acquire Kelvion - a century-old thermal management and heat exchange business - for roughly $3.4B in cash plus about $0.7B of assumed debt, an enterprise value near $4.1B, from Apollo-managed funds and Triton. This is a Tier-1 company release, not a rumour. Kelvion is expected to generate $2.3-2.4B of 2026 revenue with $350-400M adjusted EBITDA, and DATA CENTRES are its largest and fastest-growing end market at an expected $1.2-1.3B. Combined SLB and Kelvion data-centre revenue is guided above $2.0B pro forma for 2026 at roughly $300M adjusted EBITDA - about 11x 2026 EBITDA before synergies and 8.5x including roughly $120M of expected annual run-rate synergies, accretive to EPS and free cash flow per share within twelve months. Management framed it explicitly: AI is driving the most significant infrastructure investment cycle in our lifetime, and the deal more than doubles SLB's revenue opportunity per gigawatt of delivered capacity. So the largest oilfield services company in the world used an oil-shock session to buy its way into the AI power-and-cooling supply chain. That is the single most strategically consequential corporate action in this window, and it is a direct competitive problem for Track B upside rank 10 (VRT), whose structural sub-score is cut on it. MAGNITUDE BASIS: +3.99% from a ChartMill screen one hour before the Aug 31 close - intraday, flagged - with an independent recap naming SLB among the session's strongest S&P performers.	68
4	TSLA	—	Tesla rose 4.86% on Aug 31, one of the session's strongest large-cap performers, on a day when Brent closed back above $90 and the tape was repricing for a possible September rate HIKE - precisely the macro configuration under which the Track B downside thesis says Tesla should suffer most. NO SAME-SESSION CATALYST WAS CONFIRMED, and this run explicitly declines to borrow one. The Nevada Transportation Authority did approve Tesla to deploy up to 5,000 robotaxis across Clark County, replacing an interim order capped at 10 vehicles, with commercial rides expected within 30 days - but that approval is dated AUGUST 20, seven sessions before this move, and cannot be presented as the Aug 31 driver. It is scored on Track B, where a durable regulatory change belongs, and deliberately NOT scored as a Track A catalyst here. The catalyst sub-score therefore stays at 40. MAGNITUDE BASIS: intraday, one hour before the close, with independent corroboration of direction only. Market cap of roughly $1.4 trillion per a FactSet citation is flagged approximate. unverified	67
5	XOM	—	The purest expression of the macro event that defined the window. Exxon rose 2.7% on Sep 1 as WTI settled at $90.22, up $4.46 or 5.20%, and Brent settled at $94.65, up 4.6%, after US forces struck Iranian Revolutionary Guard targets following attacks on commercial shipping near the Strait of Hormuz - two tankers, one Saudi and one South Korean-owned, were hit by projectiles the previous night. Iran then threatened to halt Gulf oil exports entirely if pressure continues, which is the tail risk behind the move. Energy is the best-performing S&P sector of 2026 at roughly +43%, and Marathon Petroleum touched levels last seen in June 2011 in the same session. Ranked on a modest 2.7% because the catalyst is unambiguous, close-basis verified and sector-wide rather than idiosyncratic - which is exactly what a macro-driven window should produce.	65
6	CVX	—	Same catalyst as Exxon, reported on the same close basis by the same source, at a smaller magnitude: +2.1% against XOM's +2.7% on the Sep 1 crude spike. Ranked separately rather than folded into a sector entry because this pipeline ranks securities, not sectors, and because the spread is itself mildly informative - the market paid slightly more for the larger reserve base and refining exposure. Both carry a Zacks Rank of 3 (Hold) at the time of the recap, a Tier-2 sell-side datapoint that did NOT change with the price.	63
7	NVDA	—	Ranked low and included mainly because its behaviour is the clearest single measure of how completely the market's attention shifted. Nvidia gained about 1.5% on Aug 31 and, per the source, helped cushion the Nasdaq - six sessions after a print that more than doubled year-over-year revenue and guided fiscal-2028 growth to 70% against a 44% consensus. A 1.5% session is what that guide is now worth. By Sep 1 a Barron's headline was framing the complex as chip stocks selling off because war was hitting them hard. The catalyst sub-score reflects the FORWARD event rather than any realised one: Broadcom reports inside the horizon and is the direct read-through. MAGNITUDE: 'about 1.5%' from a single Tier-3 recap, marked approximate. No close-basis NVDA figure was obtainable for either session. unverified	62
8	ULTA	—	Recorded partly to close a loop an earlier run left open. The 2026-08-28 artifact held Ulta OUT of the ranked lists entirely, noting it had reported Q2 and raised guidance on Aug 27 but that 'a confirmed direction without a confirmed magnitude is not a ranked entry'. Two sessions later a magnitude finally appears: +4.08% on Aug 31, corroborated by an independent recap naming Ulta among the session's strongest S&P performers. The guidance raise was eventually paid for, just not on the day. That is a small but genuine data point about this tape's lag between a good print and its reward - and it sits in direct tension with the window's larger lesson, in which Palo Alto's clean beat was sold into before it was even published. Ranked last: intraday magnitude, unverified market cap, no forward catalyst.	58

▼ Falling — dailycomposite

#	Ticker	Move	Driver	Score
1	EIX	—	The largest single-session move in this artifact by a wide margin and the company's biggest one-day decline in more than 25 years. California lawmakers amended Senate Bill 492 over the Aug 29-30 weekend, stripping the wildfire-liability protections investor-owned utilities had been positioned for: no $6 billion per-incident cap on Wildfire Fund withdrawals, no replenishment mechanism, no repeal of the fund's 2028 sunset, and no adoption of Governor Newsom's proposal barring insurers from bringing subrogation claims. The 2026 legislative session ended Aug 31, forcing same-day repricing. Edison sits at the epicentre because Southern California Edison faces the Eaton Fire, with sell-side gross potential liability estimated near $13.5B before recoveries against a market value around $20.8B, and roughly 30,000 claims in litigation. What makes this the cleanest catalyst in the artifact is the control: Sempra fell only about 2-4% on heavier Texas and Mexico exposure and the XLU utilities ETF fell about 1%, isolating this as California statute risk landing on two specific balance sheets rather than a sector move. MAGNITUDE CONFLICT: -23.07% close-basis, -23% at midday to $54.22, 'as much as 24%' intraday, -19.5% premarket. Close-basis used. The +7.17% Sep 1 rebound is recorded and is intraday-basis.	92
2	PCG	—	Same catalyst as Edison; the sell-side reaction is what makes it worth ranking separately. PG&E fell 19.13% to a new 52-week low - its worst single session since March 18, 2020 - and drew a wave of downgrades: Mizuho to Neutral with a $16 target from $21, BMO Capital to Market Perform with $21 from $28, Wells Fargo to Equal Weight with $24. The analytically important detail is that BMO left its adjusted EPS estimates COMPLETELY UNCHANGED at $1.65 for 2026, $1.82 for 2027 and $1.98 for 2028, while raising its estimated wildfire-liability drag on the valuation to $10 per share from $6 and assuming uncapped liabilities beyond 2030. The operating outlook did not move at all; a statutory tail risk was repriced and took a fifth of the equity with it. BMO's scenario range runs from $3 per share in an adverse outcome to $35 if constructive reform arrives in 2027 - genuinely bimodal, not a point estimate. PG&E already sits one notch below investment grade. RETAIL COUNTER-POSITIONING, flagged: Stocktwits sentiment on PCG remained 'extremely bullish' through the crash with users calling it an overreaction - a Tier-3 crowd-positioning read only, never a fact source, but consistent with the two-sided options footprint.	89
3	PANW	—	The single most important name in this run, and it requires care about what this window can and cannot settle. The 2026-08-28 artifact registered Palo Alto's Sep 1 print as the pre-declared falsification test for the agent-security cohort re-rate: 'A beat that holds confirms a sector re-rate; a beat that is sold says the market paid for a narrative and is already taking it back.' Here is what this window actually contains. PANW fell 5.25% during the Sep 1 REGULAR SESSION, closing at $362.08 - pre-print de-risking, not a reaction, and the only part of the sequence inside this artifact's window. The company then reported after the close and beat comprehensively: revenue $3.41B against $3.35B expected and up 34% year over year, adjusted EPS $1.02 against $0.98, remaining performance obligation up 34% to $21.2B, next-generation security ARR up 63% to $9.1B with nearly $1B of net new NGS ARR added in a single quarter, $1.3B of adjusted free cash flow, and FY2027 guidance of $14.10-14.20B revenue against a $13.79B consensus with adjusted EPS $4.16-4.19. It also announced the acquisition of Console, an AI-native agentic platform. It carried the same blemish that defined the prior window's punished beats - investor concern over gross margin compression from rising cloud hosting and hardware costs, the Rubrik and Marvell objection in a third costume. THE PRICE VERDICT IS NOT IN THIS WINDOW: extended trading went roughly +6% initially then faded to about -2%, and the settled answer arrives in the Sep 2 cash session, which post-dates this artifact. The registered test is therefore RESOLVED ON FUNDAMENTALS and OPEN ON PRICE, and is carried forward as such rather than declared either way.	85
4	DELL	—	Dell fell 5.72% on Sep 1 ahead of its own after-the-bell print, in the same pre-earnings de-risking pattern as Palo Alto and on the same session. Two independent sources corroborate: a 24/7 Wall St. session note groups Dell with Axon, Digital Turbine, Cava and SentinelOne as names that shed more than 6.5% in a single session, and the Motley Fool midday piece records Dell slipping ahead of earnings. As with PANW, the RESULT and the market's verdict fall outside this window and are not scored. What is scored is the setup, and it is notable: an AI-server and storage name sold 5.7% into its own print, on the session the 10-year reached its highest since January 2025, is consistent with this window's pattern - anything whose value depends on distant cash flows was marked down first and reported second. MAGNITUDE BASIS: -5.72% from a ChartMill screen one hour before the close, intraday rather than close-basis, and the corroborating characterisation ('more than 6.5%') is larger. Flagged, not averaged.	79
5	CRWD	—	A textbook two-sided window and the cleanest illustration of how quickly the prior run's central theme decayed. CrowdStrike rose 5.03% on Aug 31, extending the recovery from its record Aug 27 print - one recap noted it had moved back above its short-term moving averages with a 14-day RSI around 62, positive momentum without being extended. It then fell 6.90% on Sep 1 with no CrowdStrike-specific news, in sympathy with the Palo Alto pre-print de-risking and the broader rate-driven software selloff. Placed on the falling side under the standing placement rule because the Sep 1 decline is both larger and close-basis verified while the Aug 31 gain is intraday-basis. The substance: six sessions after its best day in company history the market took roughly a third of that gain back on somebody else's earnings anxiety, which is exactly the fragility the prior artifact flagged when it declined to promote this cohort into Track B on one session's evidence. That restraint looks correct so far; the Sep 2 verdict on PANW settles it.	69
6	ORCL	—	The Track B downside book's top-ranked position, working on precisely the mechanism the prior runs isolated - and ranked here because the move is large enough to stand on its own. Oracle fell 5.83% on Sep 1, its third straight session of losses, explicitly attributed to rising bond yields and renewed inflation concerns. The 2026-08-28 artifact concluded that the residual short book 'has quietly become a RATES position rather than a capex position' and that Oracle was 'now purely a bet on financing cost'. Within days the 10-year reached 4.75%, its highest since January 15 2025, the 30-year settled at 5.243%, Japan's 10-year briefly touched 3% for the first time in thirty years, and Bloomberg reported US 30-year yields have not been this high for this long since 2006. The position moved as designed. MAGNITUDE CAVEAT, stated plainly: the -5.83% figure comes from a ChartMill intraday screen an hour before the close, and the only corroboration is a Tier-2 aggregator saying 'around 5%'. Two soft sources agreeing on direction and rough size is weaker evidence than this entry's rank implies, and it is flagged rather than upgraded.	69
7	AXON	—	The S&P 500's single biggest decliner on Sep 1 at -8.52%, with no confirmed company-specific catalyst - which is the point of including it. Axon is a high-multiple, long-duration growth name and it led the index lower on the session the 10-year hit its highest since January 2025 and September rate-hike odds sat at 57.5%. The Motley Fool framed it exactly that way: higher yields and increased volatility weighed heavily on tech and growth names, as evidenced by the index's biggest loser. A 24/7 Wall St. note independently groups Axon with Dell, Digital Turbine, Cava and SentinelOne as names shedding more than 6.5%. Ranked last despite the second-largest confirmed magnitude precisely because the driver is inferred rather than confirmed and the options record is empty - a big move with no verified cause and no positioning data should not outrank a documented one. MAGNITUDE CONFLICT: close-basis -8.52% is used; a ChartMill screen an hour before the same close showed only -1.60%, which cannot be reconciled with either the close-basis figure or the independent 'more than 6.5%' characterisation, and whose own Aug 31 and Sep 1 AXON prices are internally inconsistent with that label. Treated as a bad label rather than a competing measurement. unverified	63

B · One-Year Conviction

Asymmetric 12-month skew

NO FULL MARKET-CAPITALIZATION VERIFICATION PASS WAS RUN FOR TRACK B. Track B market_cap_usd is null and flagged except AAPL ($4.6 trillion) and TSLA (~$1.4 trillion per a FactSet citation, flagged approximate). All nineteen positions are unambiguous large caps whose eligibility is not in question, but the pipeline's standing rule is to flag rather than estimate. Valuation figures in the theses are carried from prior artifacts and are five weeks stale in most cases. Tier-1 sources standing behind these theses: Micron FQ3-2026 via SEC EDGAR, NVIDIA IR, GE Vernova Q2-2026 IR, Alphabet Q2-2026 slides, FactSet Earnings Insight, the Palo Alto FY2026 8-K, and newly this run the SLB Kelvion release.

▲ Upside skew — 1yrconviction

Ticker	Thesis	Key risk	Score
NVDA	Unchanged and still the best-evidenced position on either list. FQ2 revenue of $96.22B more than doubled year over year with adjusted EPS of $2.22 against $2.09, and guidance implied roughly 70% fiscal-2028 revenue growth where the Street had modelled 44%. The bear case has never been this quarter; it is that the capex cycle rolls over in 2027-28, and the company guided directly at that window. What this window adds is a caution about the ENVIRONMENT rather than the thesis: the market spent two sessions repricing for a possible September hike and a Middle East supply shock, and in that setting an out-year growth number is worth less than it was on Aug 27 even if it is equally true.	The out-year guide bought roughly one session of outperformance and nothing since - it did not generalise to the sector and is not generalising over time; 30-day implied volatility was at 33 against a 52-week range of 32-55 as of Aug 28, near the annual LOW, so the options market entered a war-and-rates shock pricing almost no further surprise in the largest name in the index; Rate risk is now the dominant variable: the 10-year reached its highest since January 2025 and September HIKE odds sit at 57.5%; Beta near 2.2 makes this the wrong vehicle if the capex thesis is wrong; Broadcom reports inside this horizon and is the nearest read-through to the same demand question; CXMT's memory capacity response remains an unresolved input-cost variable	87
TSM	The unavoidable chokepoint of the AI buildout and the only large-cap in the complex that converts the capex boom into cash rather than consuming it. Full-year revenue growth guided above 40% with capex lifted to $64B; pricing power sits simultaneously over Nvidia, AMD, Broadcom and Apple. Nothing in this window bears on it directly. The one adjacent consideration is uncomfortable: a Taiwan-exposed asset in a window defined by a widening Middle East conflict and a global bond selloff carries a geopolitical correlation that is easy to forget when the news flow is about Hormuz rather than the Strait of Taiwan.	Taiwan geopolitical tail risk is the entire bear case and is not diversifiable - and this window was a live demonstration of how fast a shipping chokepoint can reprice an asset class; Customer concentration in Nvidia; Rising capex intensity compresses free-cash-flow conversion; A 2027 hyperscaler capex cut hits with a two-to-three-quarter lag; THIRD consecutive run with no name-specific evidence - the absence of falsification tests is a weakness, not a comfort	87
MSFT	Thesis confirmed on the tape in the July window and therefore partly spent. FQ4 revenue $90.01B against $87.62B expected, Azure +43% constant currency against a 40.2% estimate, annual Azure revenue past $100B for the first time. From here the 12-month case rests on Azure holding a 40%-handle growth rate against a much larger base. The doubling of paid Microsoft 365 net seat additions quarter on quarter is the most useful new detail this window produced for any upside position, because it speaks directly to the seat-based monetisation question this same book is simultaneously SHORT via Workday - the same mechanism, opposite conclusions, inside one book. ↔ deep-dive	The cheap-entry argument is gone: this is a growth-durability call, not a re-rating call; Azure growth is materially OpenAI-linked, concentrating exposure to one counterparty's funding in a window when credit conditions visibly tightened; Moved lower on Aug 31 with the rest of the hyperscaler complex; leadership has not returned here; Capex raised again with the last print; INTERNAL BOOK TENSION: the M365 seat-addition strength and the WDAY seat-decay short cannot both be fully right	83
AVGO	The custom-ASIC leg is the structural AI trade: every hyperscaler dollar spent reducing Nvidia dependence is by definition spent with Broadcom. Q1 FY2026 AI semiconductor revenue $8.4B, up 106% year over year on total revenue of $19.31B, with a $73B AI backlog deliverable over 18 months. This position now sits directly on top of the most consequential event in the catalyst horizon, and the comparable is unambiguous: Marvell beat, raised FY27/FY28 growth guidance, disclosed a Google custom-chip arrangement worth up to $120B through fiscal 2033, and fell 10.3% because the money is too far away. Broadcom faces the identical question about the identical customers, in a tape that has since become materially more hostile to distant cash flows.	Reports Sep 2 - INSIDE the horizon and within hours of this artifact. Any reader acting on this entry is acting into an event; Customer concentration (Google, Meta, OpenAI), and Google has publicly diversified toward Marvell; The '$100B AI revenue in 2027' figure is a CEO statement on a call, NOT formal guidance; Options were pricing roughly a 7.6% post-earnings move with neutral positioning as of Aug 28 - no directional cushion either way, and that read is now five sessions stale and pre-dates the oil and rates move; A beat sold on out-year timing would convert the custom-silicon de-rating from a Marvell event into a cohort event	81
GEV	Electricity, not silicon, is the binding constraint on AI. Q2 2026 (Tier 1, company release): orders $24.2B up 88% organic, backlog $176B, gas power equipment backlog from 100GW to 116GW, revenue $11.1B up 22%, free cash flow $5.1B in the quarter - more than all of 2025 - with FY26 FCF guidance raised from $6.5-7.5B to $11.5-12.5B. Still the strongest verified estimate-revision evidence on either list. The complication this window introduced is new and real: the ability of regulated utilities to fund large equipment orders is a function of their own cost of capital, and California just demonstrated how quickly statute can move that.	Highest headline multiple on this list at roughly 52x forward, into the highest sustained 30-year yields since 2006; NEW THIS RUN: California's SB 492 outcome shows utility cost of capital is a live legislative variable, and utilities are the customer base; Wind segment remains a drag; Turbine slot reservations are not firm revenue; Fell more than 7% on its own Jul 22 print on margin concerns - the market is not paying for backlog alone; No catalyst inside this horizon	76
MU	SPLIT CONVICTION and unchanged. Bull, intact: FQ3 2026 (Tier 1, SEC-filed) revenue $41.46B against $9.30B a year earlier, GAAP diluted EPS $24.67, operating cash flow $25.39B, FQ4 guidance $50.0B plus or minus $1.0B at roughly 86% gross margin, and 16 supply agreements with 14 carrying minimum commitments of roughly $100B through 2030. Bear, unchanged: CXMT's first-half revenue grew more than 870% to roughly $22.36B, converting the oversupply thesis from a capacity forecast into a revenue-recognition fact. The bull leg rests on contracted volume; the bear leg rests on a competitor's revenue line. Neither moved this window. ↔ deep-dive	CXMT H1 revenue up more than 870% to ~$22.36B - the oversupply thesis has a number attached; Peak-cycle earnings at a trough multiple - the classic value trap in semis; An ~85-86% gross margin is roughly 25 points above any historically sustainable level; Customer inventories 7-9 weeks against an 8-week warning threshold and a 10-week exit trigger; Highest-variance name on either list - the 12-month distribution is bimodal, not merely uncertain; Michael Burry's disclosed short near $880 has not been retired; Persistent top-tier retail options crowding across three runs with no directional print is a warning about who else is in the trade	76
GOOGL	Best full-stack AI position in the world - TPUs, models, distribution and cloud - and the only Mag-7 name whose revenue growth ACCELERATED on AI. Q2 2026: revenue $119.8B up 24%, operating income $40.8B up 30%, Google Cloud $24.8B up 82% with cloud operating margin expanding to 35.6% from 20.7%, and a $514B cloud backlog. The uncomfortable pattern is now several runs old: the structural case keeps strengthening and the stock keeps underperforming, and in a window where the binding constraint became the cost of capital rather than the quality of the asset, a company guiding to $195-205B of 2026 capex with negative free cash flow is on the wrong side of the variable that actually mattered.	2026 capex guided to $195-205B, Q2 free cash flow -$5.9B (first negative quarter since the 2004 IPO), buybacks suspended - and financing conditions tightened materially this window; Street models FCF going from +$13B in 2026 to -$13B in 2027; EARNINGS QUALITY: Q2 diluted EPS of $9.11 was materially inflated by unrealized equity-securities gains and is deliberately excluded from the valuation sub-score; Antitrust remedies remain live; Named as a specific Dow drag on Aug 31 - another run in which this position fell while its structural score stayed at the top of the book	75
LLY	Clear structural winner of the GLP-1 duopoly. Lilly is compounding roughly 29% EPS while Novo has guided 2026 to a 5-13% constant-currency sales decline and failed the ZEUS cardiovascular outcomes trial that was its most visible attempt to build a second franchise. Oral orforglipron extends Lilly past injectable supply constraints. Carried as much for portfolio construction as for absolute upside - the only top-10 upside name with zero exposure to the hyperscaler capex question, which is worth more in a window where the capex names all fell together on a rates shock.	THE Q2 PRINT REMAINS UNVERIFIED ACROSS THREE CONSECUTIVE RUNS - the longest-standing information hole in the Track B book, and it must be closed before the next scoring cycle; Consensus PT implied only ~11% upside as of the last verified read; US drug pricing / most-favored-nation policy risk; ~34x forward leaves no room for a manufacturing stumble; A rival's trial failure is a relative, not absolute, improvement; This window's healthcare leadership went to vaccines and large-cap value, not to GLP-1	75
META	CONTRARIAN and still unresolved. You are paying roughly 17.6x forward - the cheapest multiple in mega-cap tech - for a business that grew revenue 28% to $60.80B with ad impressions up 14% and price-per-ad up 12%. The core business is accelerating. But Q2 EPS of $6.18 missed $7.22, operating margin compressed to 31% from 43%, free cash flow fell to $784M from $8.55B, and 2026 capex is guided to $130-145B. The structural flaw - capex with no third-party revenue offset - is unaddressed, and this window made the financing side of it materially worse: a company spending $130-145B it must fund internally, in a market where the 30-year has been above 5% for 55 days this year, the most since 2006. ↔ deep-dive	THE STRUCTURAL FLAW, unaddressed for four runs: unlike MSFT, GOOGL and AMZN, Meta has no external cloud revenue line to monetize the buildout; Reality Labs lost $4.03B in the quarter; FOURTH consecutive run on watch_for_invalidation with no resolving evidence in either direction. HARDENED CONDITION, registered now: at the next quarterly print, capex must translate into a disclosed revenue line or a credible margin path, or this position is RETIRED at that print regardless of multiple. No further extension on the grounds that no print occurred; No catalyst inside this horizon, so the flag will carry again; The cheap multiple has been cheap for four runs and has not been the reason anything happened	66
VRT	Pure play on data-center thermal management and power distribution - the physical bottleneck layer. Rack densities from Rubin-class systems make liquid cooling non-optional, converting a cyclical hardware business into a content-per-rack growth story. Nvidia's 70% fiscal-2028 revenue guide remains the cleanest demand input for that thesis. But the moat argument weakened materially this window: the demand is now attractive enough that a $4.1B acquisition was executed to enter it, which is what happens to a bottleneck when the bottleneck becomes visible. Ranked last for a fourth consecutive run, now with a concrete reason rather than merely an absence of resolution.	COMPETITIVE ENTRY IS NO LONGER HYPOTHETICAL: SLB paid ~$4.1B for Kelvion on Aug 31 specifically to build data-centre thermal management scale, guiding to >$2.0B of combined pro forma 2026 data-centre revenue; Highest beta on this list to any hyperscaler capex cut; Eaton drew unusual put volume this window; Schneider remains a competitor; The last observed name-level options positioning was bearish and is now five weeks stale; it is retired rather than extended; The Q2 revenue miss that took the stock down 17.26% on Jul 29 is the execution slip a ~29x multiple cannot absorb repeatedly, and the multiple is meeting the highest sustained long-end yields since 2006	62

▼ Downside skew — 1yrconviction

Ticker	Thesis	Key risk	Score
ORCL	The only name on either list where the risk is solvency-adjacent rather than valuation-driven, and this window was the first real test of the narrowed thesis. Oracle levered its balance sheet to fund a roughly $300B OpenAI contract and the credit market repriced it: CDS spreads hit a record 198.23bp and S&P downgraded to BBB-, one notch above junk. Total debt $167.43B against $43.06B of equity, TTM free cash flow -$23.69B, with roughly $40B of further financing planned for FY2027. The demand question is settled AGAINST this position - OCI revenue grew 84% to $4.89B with OpenAI, Meta and NVIDIA signing GPU-compute contracts - so this is purely a bet on financing cost. Financing cost rose sharply and the stock fell three sessions running. Now ranked first on the downside book, on merit rather than churn.	Three down sessions is a fortnight's evidence for a twelve-month thesis, not a verdict; The -5.83% figure rests on a ChartMill intraday screen plus a Tier-2 aggregator's 'around 5%' - softer sourcing than a rank-1 position should ideally carry, and flagged as such; Citi's 90-day positive catalyst watch with a $330 target remains live and dated - an explicit contrarian bet by a named counterparty; OCI +84% to $4.89B settles the demand question against the thesis permanently; A successful $40B raise at reasonable spreads collapses the CDS and the thesis with it; Consensus PT of $244.12 sits far above spot - the Street is emphatically not on this side; September earnings sit just OUTSIDE this horizon, so the position again carries an unhedged event within weeks	78
NVO	The cleanest verified downward-revision case on either list. The company guided 2026 to a full-year constant-currency sales DECLINE of 5-13% against 10% growth in 2025 and cut US GLP-1 prices by up to 70%, defending volume at the cost of mix. On Jul 31 ziltivekimab missed its ZEUS primary endpoint outright with a hazard ratio of 0.99 (95% CI 0.88-1.11) across more than 6,300 patients against a market Jefferies sizes above $10B annually. UBS modelled only 1.7% of NPV but expected a 2-3x reaction because the failure compounds a run of R&D setbacks. Nothing this window bears on it.	THE Q2 PRINT REMAINS UNVERIFIED ACROSS THREE RUNS - ranked second on downside conviction while carrying an unread quarter is a real limitation, stated rather than hidden; A trailing P/E near 12 is genuinely cheap and limits downside velocity; HERMES and ARTEMIS both continue, reading out H1 2027 in distinct populations - a single failed trial is not a failed molecule; 2026 adjusted operating profit guidance was explicitly maintained; the Q3 impairment is non-cash; Roughly 25% came out over twelve months plus ~9% on the ZEUS news - a meaningful portion is priced; This window's biotech leadership went to a cancer vaccine, which says nothing about GLP-1 but is a reminder that the sector rewards pipeline surprises violently	77
AAPL	Thesis confirmed on the tape in the July window and now taking its first real damage. The FQ3 print delivered the predicted shape: a genuine beat (revenue $109.4B up 16%, EPS $2.02 up 29%) undermined by a forward guide of 9-11% revenue growth against 12% consensus, with Services at $30.74B and Greater China both short. Management attributed the guide to advanced-chip and MEMORY supply constraints, making Apple a price-taker to the same shortage enriching the memory complex. That analysis is unchanged and unrefuted. What changed is that the market has been handed a fresh story - a new CEO at the largest company in the world - and it bought that story on a day it sold almost everything else. The position appears on Track A RISING rank 2 and Track B DOWNSIDE rank 3 simultaneously, in opposite directions, which is the honest representation of a correct thesis meeting an adverse catalyst. ↔ deep-dive	THE NARRATIVE RESET HAPPENED AND WORKED: +2.61% on a -1.03% Nasdaq session, on no fundamental news; $123.3B of TTM free cash flow and the largest buyback in history put a hard floor under it; Wells Fargo RAISED its target to $350 and BofA reiterated $380 on the FQ3 print - the sell-side is genuinely split; Supply constraints are a timing problem, not a demand problem; management said so explicitly; A new CEO's first quarters typically come with reset expectations and kitchen-sink latitude, which cuts against a short; Roughly $350-500B of value came out in one session on Jul 31 - much of the easy move is done	75
CRWV	The thesis remains bifurcated with the demand leg formally abandoned. DEMAND LEG: dead, and stated as such rather than quietly dropped. Q2 revenue up 112% to $2.58B, a $104B backlog, named business with Anthropic and Meta, guidance raised, and a Freedom Capital Markets note projecting 2026 adjusted operating margins rising from 1% in Q1 to 15% in Q4. Anyone short CoreWeave on the belief that AI infrastructure demand evaporates is wrong. CREDIT LEG: alive, and the macro conditions for it intensified sharply this window. Capex guidance was raised to $35-39B against roughly $35B of existing debt funding depreciating GPUs with -$10.6B of free cash flow, Altman Z-Score 0.36 and Piotroski F-Score 2. The precedent from Aug 18 - a 12.10% single-session decline specifically as the 30-year hit 5.32% - is the behaviour this position is built on, and long-end yields went higher still this window.	NO CRWV PRICE PRINT WAS VERIFIED IN THIS WINDOW. The macro moved hard in the thesis's favour and this pipeline cannot confirm the stock responded. That is the central limitation of this entry and why the sub-score moves are small; THE DEMAND LEG IS DEAD AND IS NO LONGER PART OF THIS THESIS; A sell-side note projects adjusted operating margins reaching 15% by Q4 and adjusted EBITDA rising to 69% - directly against the cash-burn framing; Contracted revenue with investment-grade counterparties materially de-risks the near term; Wall Street price targets span $74 to $250 - no consensus to fade; Borrow cost is likely punitive on a name this crowded; FOURTH consecutive run on watch_for_invalidation - see the hardened condition in the ledger	72
INTC	A 4.5x move in twelve months on a company still losing roughly $11B a year, driven by policy and partnership headlines rather than profits - $8.9B of CHIPS funding converted to a government equity stake, a $5B Nvidia investment, an Apple chip-making agreement. At roughly 54.8x forward it remains the most expensive large-cap semi on either list with the weakest competitive position and no trailing earnings. The Jul 30 beat-and-raise the market paid 12.53% for remains the one genuinely uncomfortable datapoint, and multiple quiet windows have now passed without either confirming or refuting it.	THESIS UNDER PRESSURE since the Jul 30 beat-and-raise, and consecutive quiet windows have not resolved it; A sovereign/strategic backstop makes a fundamental short genuinely dangerous - the US government is an equity holder; 18A/14A yield news is binary and headline-driven; Server CPU demand is genuinely strong; Consensus PT sits well ABOVE spot; HARDENED CONDITION: the next Intel print either shows a third consecutive rewarded beat - retire on the PLTR precedent - or it does not, in which case the flag clears and the position scores normally. No fourth run on an open-ended flag	71
MRK	Materially weakened this run but not retired. The original argument stands on its arithmetic: Merck rallied 57% INTO the Keytruda loss of exclusivity, FactSet attributed the Health Care sector's Q2 downward revision specifically to Merck and Gilead, the company announced $3B of annual cost cuts ahead of the cliff, and roughly 21x forward for 5.6% EPS growth against a patent cliff is the worst growth-adjusted multiple among mega-cap pharma. What has changed is the second-franchise question. The Moderna-partnered melanoma vaccine is no longer a pipeline line item; it is the asset that made a $23B-plus biotech the best performer of August. That is a real hole in the thesis, and the sub-scores are cut to reflect it rather than the position being defended.	THE SECOND-FRANCHISE ARGUMENT IS NOW CONTESTED: the Merck-partnered melanoma vaccine drove Moderna up roughly 152% in August and 9.93% on Sep 1; THE AUG 17 PDUFA OUTCOME REMAINS UNKNOWN ACROSS THREE RUNS - subcutaneous Keytruda conversion could materially blunt the cliff, and this is the third run in which the single most important binary for this thesis has gone unretrieved; National priority vouchers reported for Merck cholesterol and cancer therapies - a regulatory tailwind, direction confirmed but magnitude unquantified; The last observed options skew was 2:1 toward CALLS into the Aug 4 print; A 2.6% dividend limits downside velocity; Consensus PT is still above spot; If the next run cannot retrieve the PDUFA outcome, retire for lack of evidence rather than carry a thesis whose central binary is unknown	70
TSLA	Roughly $1.4 trillion of market capitalization resting on $3.81B of earnings. The underlying auto business is a roughly 14%-growth, 3.7%-net-margin manufacturer; the valuation is optionality on robotaxi and Optimus. The VALUATION half of this thesis is untouched and remains the strongest fundamental_valuation score on either list. Both other halves took damage. The robotaxi optionality is now REGULATORILY ENABLED at scale in a second state rather than capped at ten vehicles, which converts part of the optionality from speculative to permitted - the single most concrete adverse development this position has faced. And the discount-rate mechanism failed a live test. Retained because the valuation argument stands on its own; downgraded twice in two runs because the two supporting legs have both weakened.	THE RATE MECHANISM FAILED ITS BEST TEST: TSLA rose 4.86% on the session Brent closed above $90 and hike odds sat near 57%; NEVADA APPROVAL IS A STRUCTURAL ADVERSE EVENT: up to 5,000 robotaxis authorised across Clark County, replacing a 10-vehicle interim cap, commercial rides expected within 30 days; ESTIMATE-REVISION DIRECTION IS UNVERIFIED across several consecutive runs - the sub-score is neutral 50 rather than guessed, and the persistence of that hole is itself a weakness; Persistent retail bid; TSLA is a top-three active option on every report in this window and the last two; Consensus PT of $398.30 sits well above spot - the Street is not on this side; Rates being high is a necessary but not sufficient condition, and this window is the clearest evidence yet that it is not sufficient	70
WDAY	The rarest outcome in this book: the thesis was CONFIRMED and the trade was IMPAIRED in the same eight-hour window, and the two remain separate. Headcount-licensed HCM is the most literally AI-exposed pricing model in enterprise software, and Workday's own guidance says so - Q3 cRPO of 11-12% against a 14% Street expectation and FY2028 subscription growth of roughly 11% against 14% in Q2. But Reuters reported Silver Lake in talks to acquire the company at a market value around $43B; the stock rose nearly 18% for its best day in ten years and was halted for volatility, management declined to address the talks on the Aug 27 call, and the board authorised a new $4B open-ended buyback. A short facing live take-private talks plus a company bid is uninvestable regardless of how right the fundamental thesis is.	LIVE LBO RISK IS THE WHOLE PROBLEM: Reuters-reported Silver Lake talks at roughly $43B, with Needham flagging a possible $240-250 deal range. A confirmed bid ends this position at a loss regardless of fundamentals; An unscheduled binary that can land on any day - it did not land this window, which is not evidence it will not; A new $4B open-ended buyback puts a company bid under the stock; The stock is up roughly 48% in three months - the entry is far worse than when this position was opened; Q2 itself BEAT: non-GAAP EPS $2.75 against $2.61, subscription revenue $2.471B up 13.9%; INTERNAL BOOK TENSION: this pipeline is simultaneously long MSFT partly on accelerating seat additions and short WDAY on seat-model decay; WATCH_FOR_INVALIDATION: if Silver Lake talks are confirmed or a bid is tabled, retire immediately rather than re-score	65
AMD	AMD trades at a large premium to Nvidia's forward multiple while being the structurally weaker accelerator franchise - squeezed from above by Nvidia's ecosystem and from below by Broadcom, Google TPU and Meta MTIA custom silicon. Nvidia's 70% fiscal-2028 guide and Marvell's disclosed Google arrangement worth up to $120B through fiscal 2033 strengthened both flanks of that squeeze in an earlier window; nothing since has changed either. Remains a relative-value short against NVDA far more than an absolute one, and it is ranked last because the evidence base is the thinnest on the book.	THE AUG 4 EARNINGS RESULT REMAINS UNVERIFIED ACROSS THREE RUNS - this position is scored on a thesis whose most recent quarter this pipeline has never read; Genuine second-source demand from hyperscalers wanting a Nvidia alternative is real and structural; Server CPU share gains against Intel are real and margin-accretive; A 46.6% revenue growth forecast is not fantasy; Ranked last precisely because the evidence base is thinnest here, and a position that cannot be evidenced should be sized accordingly or retired	65

C · Options Heat

Where the premium is paying up

Ticker	Signal	Read	Implication	Lag
PANW	pc_skew	Weekly implied volatility rose from 117 (Aug 31 mid-session) to 125 (Sep 1 mid-session) against a September term of 78 then 77, versus a 52-week range of 25 to 78 - the weekly printed at and then above the TOP of the annual band. The call:put ratio simultaneously FLIPPED from 1.2 calls to 1 put to 1 call to 1.1 puts. Independently, the September-18 expiration carried 52,657 calls against 55,510 puts of open interest as of Aug 30, a ratio of 1.05. Options were pricing an approximately 8.5% earnings move.	The most coherent options picture in this artifact: three separate readings - term structure, intraday skew reversal, and standing open interest - all say the book de-risked into the print rather than positioning for the beat that arrived. That matters for the cohort question. The prior window's lesson was that put-skewed software books were run over by up moves; here the book de-risked and the stock fell 5.25% BEFORE the print, the opposite sequence. Note the base rate that framed the setup: PANW had beaten estimates six straight quarters while averaging a -3.74% day-of reaction, with each of the last three declining 6-7%.	Market Rebellion figures are broker-desk mid-session snapshots taken Aug 31 and Sep 1, published BEFORE the event and non-final. Open-interest counts come from a Tier-2 editorial note dated Aug 30, two sessions before the print, not an exchange feed. No post-print vol/OI was obtainable. Ratios carry no bid/ask side tagging, so 'more puts' is equally consistent with put buying and put selling.
HYG	iv_spike	HYG, the iShares iBoxx High Yield Corporate Bond ETF, appears on the Market Rebellion INCREASING-implied-volatility list on the Sep 1 mid-session report - a list containing only two names that session. No IV level, prior value or 52-week range was published.	The most consequential entry in this section despite being the thinnest, because of what sits underneath it. This book's residual short exposure was reclassified from a capex bet to a rates-and-credit bet, and HYG is the most direct free-tier read on corporate credit stress available anywhere in this pipeline's source set. Rising implied volatility in high-yield credit, on the session the 10-year hit a 20-month high and the 30-year settled at 5.243%, is the ORCL and CRWV mechanism showing up in an instrument rather than in commentary. It is emphatically NOT a measurement of that stress - list membership with no level attached cannot tell you whether IV rose one point or ten.	Unranked list membership with NO implied-volatility level, no prior comparison and no 52-week range published. Mid-session broker-desk snapshot, intraday and non-final. No CBOE index-level put/call ratio was obtained for either session; the official daily statistics page has returned navigation-only content across multiple runs and was not retried.
EIXPCG	vol_oi	Both appear on the Aug 31 increasing-implied-volatility list, which contained only six names all session (DPRO, EIX, PCG, SRE, AGNC, NKE), and then across the increasing unusual option volume, increasing unusual CALL volume and increasing unusual PUT volume lists on Aug 31 and both Sep 1 reports. PCG additionally enters 'popular stocks with increasing option volume' on Sep 1 pre-market - six list appearances in two sessions, on both sides of the book.	Simultaneous call-side and put-side unusual volume with implied volatility rising is the signature of a two-sided repricing rather than a directional crowd - consistent with a genuine statutory shock where the distribution widened in both directions rather than simply shifting down. BMO's published scenario range for PG&E of $3 to $35 per share is the fundamental analogue of that options picture. Corroborating retail read: Stocktwits sentiment on PCG stayed 'extremely bullish' through a 19% decline, a Tier-3 crowd-positioning indicator only.	Every figure here is unranked LIST MEMBERSHIP. No IV level, skew ratio, contract count or volume figure was published for either name on any report. Breadth and persistence of appearance is the entire signal, which means this measures attention, not size or direction. Barchart Unusual Options Activity and Market Chameleon render client-side and returned page chrome only, as in every prior run.
DELL	pc_skew	September-4 weekly call implied volatility rose from 127 (Aug 31) to 139 (Sep 1) against a September term of 80 on both dates, versus a 52-week range of 32 to 100 - from roughly 1.27x to roughly 1.39x the top of the annual band. The call:put ratio FLIPPED from 1 call to 1.3 puts to 1.1 calls to 1 put across the same 24 hours, into a Sep 1 after-the-bell print.	A direct and instructive counterpoint to PANW on the same two sessions. Into the same close, the Dell book got more BULLISH while the Palo Alto book got more BEARISH, both on rising implied volatility, and Dell fell 5.72% in the regular session anyway. Two skew reversals in opposite directions on the same day says the free-tier skew signal is name-specific noise as often as information - a useful corrective to the prior run's finding that put skew was a reliable contrarian input in software.	Pre-event broker-desk mid-session snapshots, intraday and non-final. No side tagging, so a rising call ratio is equally consistent with call buying and call selling. No post-print data obtainable.
MDB	iv_spike	September-4 weekly call implied volatility at 219 against a September term of 109, versus a 52-week range of 34 to 99 - roughly 2.2x the TOP of the annual band, the most extreme term structure in this window. Call:put ratio 1 call to 1.7 puts. Credo Technology (CRDO) sits alongside at weekly 159 against September 98, versus a 52-week range of 67 to 124.	Recorded because it is the largest event premium in the window and because MongoDB is NOT ranked anywhere in this artifact - it produced no confirmed session move in either direction and was never a Track A candidate. Publishing it keeps this section honest about where the extreme positioning actually was: not in the names that moved, but in the ones with imminent prints. The 1:1.7 put skew is the same configuration decisively wrong-footed across CRM, OKTA and SNPS in the prior window, which is worth watching rather than acting on.	Market Rebellion mid-session Sep 1, pre-event and non-final. Broker-desk snapshot, not exchange data. No contract counts published.
CROWDING_WATCH	vol_oi	Names on the 'popular stocks with increasing option volume' AND 'active options' lines across all three reports in this window (Aug 31 mid-session, Sep 1 pre-market, Sep 1 mid-session): INTC, MU, SPCX, PLTR, MSTR, SOFI, AMD, MRVL. NVDA, TSLA, AAPL and AMZN head the active-options line on every report. NEW ENTRANTS on Sep 1: ORCL, HOOD, HTZ, PFE, NIO. DEPARTURES: CRWD and AVGO drop out of the Sep 1 mid-session lists entirely.	The crowding picture is stable across three consecutive runs and continues to sit somewhere other than where money is being made or lost. Intel and Micron lead the retail options bid for a third run while producing no confirmed price move in this window at all; the names that actually drove the tape - EIX, PCG, AXON, the energy complex - are largely absent or newly arrived. Two entries worth isolating: ORCL appearing for the FIRST time in this pipeline's crowding record, on the session it fell for a third straight day; and PLTR remaining on every crowding list runs after being retired from Track B, a standing reminder that crowding is not a thesis.	Unranked membership lists with no volumes, IV levels or skew ratios attached. Useful for attention and crowding, useless for direction or size. Departures can reflect other names crowding in rather than activity falling, so absence is weaker evidence than presence.
POST_EVENT_CRUSH	iv_spike	The prior window's earnings cohort appears on the DECREASING-implied-volatility lists across all three reports in this window: MRVL, OKTA, RBRK, IREN, ESTC, GAP, AFRM, ULTA, ADSK, CRM, SNPS, S, DLTR and NVDA all recur. OKTA and MRVL appear on every single decreasing-IV list across both this window and the last.	Textbook post-event volatility crush working through an entire cohort on schedule, closing the loop on the prior run's options section. The names that carried weekly implied volatility at two to three times the top of their annual bands into the Aug 26-28 prints have now spent four consecutive sessions on the decreasing side. For anyone long those weekly options, direction was necessary but nowhere near sufficient - the base rate this pipeline flags on every event trade, demonstrated here at unusual scale.	Unranked list membership with no IV levels attached, so the SIZE of the crush is unmeasurable - only its existence and persistence. Mid-session and pre-market broker-desk snapshots.

D · Catalyst Calendar

Upcoming events

Date	Event	Tickers	IV move
2026-09-02	Broadcom Q3 FY2026 earnings, after the close. DATE CONFLICT RESOLVED: the 2026-08-28 artifact carried this on both Sep 2 and Sep 3; a Schwab investors' calendar published Sep 1 places it on Sep 2 and that is adopted. Consensus looks for roughly 91.5% EPS growth to $3.24 on revenue up 84.1% to $29.4B, with semiconductor solutions more than doubling from $9.2B to $18.5B. Options were pricing an approximate 7.6% move with neutral positioning as of Aug 28. The largest single-name event in the horizon, carrying two registered conditions: it is the falsification test for Track B upside rank 4, and its reaction SHAPE is the pre-registered promotion trigger for MRVL to the downside book.	AVGO	high
2026-09-02	Snowflake Q2, HPE Q3, NetApp Q1 and Five Below earnings. Snowflake is the cleanest remaining read-through to the enterprise-software re-rate question the Palo Alto print left open on price. HPE and NetApp sit alongside Dell as the AI-server and storage cohort - Dell reported Sep 1 after the close and its reaction is also outside this artifact.	SNOWHPENTAPFIVE	unknown
2026-09-02	ADP National Employment Report for August, 08:15 ET, consensus 48K against a prior 44K - a low bar that makes an upside surprise easy and a downside surprise meaningful. Also July factory orders, the Federal Reserve Beige Book, and weekly EIA crude oil inventories, which carry more weight than usual with WTI settled at $90.22. The ADP print is the leading tell for Friday's payrolls.	macro	unknown
2026-09-03	August ISM Services PMI at 10:00 ET, plus initial jobless claims, the advance goods trade balance and revised productivity and costs at 08:30. In a 57.5%-hike-probability regime with ISM manufacturing prices paid holding at 71.1, a hot services print is the more dangerous of the week's two ISM releases - services is where the sticky component of inflation lives.	macro	unknown
2026-09-03	Ciena and lululemon earnings. Lululemon is the more useful for this artifact: it reports into a setting where Nike just printed a twenty-year low and consumer discretionary is the worst-performing S&P sector of 2026 at -2.3%. A second weak athletic-apparel datapoint would make the Nike low look structural rather than idiosyncratic.	CIENLULU	unknown
2026-09-04	BLS Employment Situation - August nonfarm payrolls and unemployment rate, 08:30 ET. The dominant macro event of the horizon by a wide margin and the final monthly employment report before the September 15-16 FOMC. With hike odds at 57.5%, ISM employment having fallen to 51.2 from 52.8, and oil adding a supply-side inflation impulse the labour data cannot offset, this print plus Thursday's ISM Services are what actually set the September meeting. Index volatility should be pinned here rather than to any earlier date.	macro	unknown
2026-09-07	LABOR DAY - US equity and bond markets CLOSED. Recorded explicitly because two separate sources mis-dated this holiday in a prior run's research, and because a three-day weekend immediately after a payrolls print, with an active shooting war affecting the Strait of Hormuz, is a genuine gap-risk configuration rather than a formality.	macro	unknown
2026-09-08	Casey's General Stores earnings - the only scheduled large-cap event identified for this date. A convenience and fuel retailer reporting into a 5.2% single-session crude move is a marginally more interesting consumer read than usual. No major US macro release identified; treated as light, MEDIUM confidence.	CASY	unknown
2026-09-09	NO major scheduled US macro release or large-cap earnings identified. The New York Fed economic-indicator calendar places the next cluster on Sep 10 (initial claims, PPI, existing home sales, wholesale trade) and Sep 11 (CPI, preliminary Michigan). Recorded as 'none scheduled' with LOW confidence rather than asserted as empty - this is the outer edge of the horizon and coverage thins.	macro	unknown

E · Trade Ideas

What the data implies

AVGOneutral · track A/B

Rationale The highest-information event in the horizon, landing within hours of this artifact, which is the most important thing to say about it. The setup is unchanged and the comparable is still Marvell: beat, raised FY27/FY28 growth guidance to 45%/50%, disclosed a Google custom-chip arrangement worth up to $120B through fiscal 2033, and fell 10.3% because the money is too far away. Broadcom faces the identical question about the identical customers, with consensus looking for roughly 91.5% EPS growth on revenue up 84.1% to $29.4B. What has changed is the discount rate: the 10-year has gone to 4.75%, its highest since January 2025, the 30-year sits at 5.243% and has spent 55 days above 5% this year, and September hike odds held at 57.5% THROUGH a war escalation. A tape that refused to pay for 2033 revenue at a lower 10-year has less reason to pay for it now. The read-through matters beyond the name - a beat sold on out-year timing converts the custom-silicon de-rating from a Marvell event into a cohort event, the registered promotion trigger for MRVL.

Invalidation The volatility view has no invalidation. For the underlying Track B long: a beat sold on custom-silicon timing, following the Marvell template, would be the second instance of the same rejection and should cut the structural sub-score materially rather than be treated as noise. Gamma positioning was described as support near the $350 strike and resistance near $400 as of Aug 28 - a map, not a thesis, and five sessions stale.

Risk The earnings-date conflict carried since 2026-08-28 is resolved to Sep 2, so that execution hazard is gone. The remaining hazard is larger: the valuation figures behind the Track B thesis are roughly five weeks stale and were not refreshed this run.

PANWneutral · track A

Rationale An OPEN-CONDITION note rather than a trade, because the pre-registered test was run and this artifact cannot see the result. The 2026-08-28 artifact named Sep 1 as the falsification test for the agent-security cohort re-rate. Palo Alto delivered the beat side comprehensively: revenue $3.41B against $3.35B and up 34% year over year, adjusted EPS $1.02 against $0.98, remaining performance obligation up 34% to $21.2B, next-generation security ARR up 63% to $9.1B with nearly $1B of net new NGS ARR in a single quarter, $1.3B of adjusted free cash flow, FY2027 revenue guided to $14.10-14.20B against a $13.79B consensus, plus an agentic-AI acquisition announced alongside. It carried the same blemish that defined the prior window's punished beats - investor concern about gross margin compression from rising cloud hosting and hardware costs, the Rubrik and Marvell objection in a third costume. The stock fell 5.25% in the regular session BEFORE any of this was known, went about +6% in extended trading, then faded to about -2%. The Sep 2 close settles it and this artifact does not contain it.

Invalidation For the cohort thesis: a Sep 2 session that HOLDS the beat confirms a genuine sector re-rate and makes the CRM/OKTA/CRWD/PANW promotion conditions live. A Sep 2 session that SELLS it makes the prior run's refusal to promote correct, and means the market paid 20-28% in one session for a narrative and took it back inside a week. Note the base rate: six straight quarters of beats with an average -3.74% day-of reaction and each of the last three declining 6-7%.

Risk The single largest known blind spot in this run, structural rather than fixable: a pre-market run date places the most consequential scheduled event of the prior session's aftermath outside the window. Stated plainly rather than worked around by scoring an after-hours print as though it were a close.

ORCLCRWVTSLAshort · track B

Rationale The residual short book was reclassified from a capex bet to a rates bet. This window tested that reclassification and SPLIT it, which is the most useful thing that happened to Track B. The macro leg fired hard: the 10-year reached 4.75%, highest since January 15 2025; the 30-year settled at 5.243% and has spent 55 days above 5% this year, most since 2006; Japan's 10-year touched 3% for the first time in thirty years; and HYG drew rising implied volatility. ORCL responded exactly as designed - down 5.83% on Sep 1 for a third consecutive losing session, attributed directly to yields. TSLA did not: it rose 4.86% on Aug 31, one of the session's strongest large-cap performers, under close to ideal conditions for the thesis, and it separately carries a Nevada approval for up to 5,000 robotaxis granted Aug 20. CRWV produced no verifiable print at all. So of three positions held on one macro variable, one worked, one failed its best test while acquiring an adverse structural catalyst, and one could not be observed. The conclusion is that these were never one position, and the prior instruction to 'size them as one' was wrong in a specific and correctable way: ORCL is a credit-spread expression, TSLA is a multiple expression, and they do not respond to the same shock.

Invalidation ORCL: a successful $40B raise at reasonable spreads collapses the CDS and the thesis together; Citi's dated 90-day positive catalyst watch with a $330 target remains the explicit contrarian counterparty view. CRWV: HARDENED THIS RUN - by the next run either a CRWV-specific rate-linked drawdown or a financing event must be verified, or retire unconditionally. TSLA: structural cut for a second consecutive run; if a further window delivers rising long-end yields WITHOUT TSLA weakness, retire the rate leg entirely and leave only the valuation argument, which is a different and much slower thesis.

Risk If September delivers a hold rather than a hike, the ORCL leg loses its proximate driver immediately. The deeper risk is the one this window exposed: a book that assumes three positions share a factor, and discovers under stress that they do not, has been mis-sized in both directions.

MRKshort · track B

Rationale Flagged as the position most damaged by this window and the one most likely to be retired next, so the reasoning is on the record before rather than after. The thesis is that Merck rallied 57% into the Keytruda patent cliff with no credible second franchise, at roughly 21x forward for 5.6% EPS growth - the worst growth-adjusted multiple in mega-cap pharma - with FactSet attributing the Health Care sector's Q2 downward revision specifically to Merck and Gilead, and $3B of announced annual cost cuts reading as defensive. This window supplied direct evidence against the load-bearing clause. Moderna rose roughly 152% in August, the best-performing security of the month, and a further 9.93% on Sep 1, on positive late-stage results for a melanoma cancer vaccine JOINTLY PRODUCED WITH MERCK. A partner's equity more than doubling on a shared asset is close to the definition of the credible second franchise this thesis denies exists. Separately, Merck cholesterol and cancer therapies are reported to be receiving national priority vouchers. Structural and revision sub-scores are cut rather than the position defended.

Invalidation REGISTERED NOW, two conditions, either sufficient. First, if the Aug 17 KEYTRUDA QLEX subcutaneous PDUFA is confirmed as an approval, subcutaneous conversion materially blunts the cliff and the position should be retired. Second, if the Moderna-partnered melanoma programme reaches a regulatory filing acceptance, the second-franchise clause is dead and the position should be retired regardless of multiple. Additionally: if the next run cannot retrieve the Aug 17 PDUFA outcome after a fourth attempt, retire for lack of evidence rather than carry a thesis whose central binary is unknown.

Risk This position has now been scored across three consecutive runs without its single most important binary being retrieved. That is a research failure, not an analytical one, and it is why the invalidation condition includes a retire-for-lack-of-evidence clause. A 2.6% dividend and a consensus price target above spot both limit downside velocity independently.

EIXPCGneutral · track A

Rationale An ANALYTICAL note rather than a trade, because the correct position is that this book has no edge in California legislative outcomes and should say so. What happened is unambiguous: SB 492 was amended over the weekend to omit the $6B per-incident cap on Wildfire Fund withdrawals, any replenishment mechanism, repeal of the fund's 2028 sunset, and the proposal barring insurer subrogation claims, and the 2026 legislative session ended Aug 31, forcing same-day repricing. EIX fell 23.07%, its worst session in more than 25 years; PCG fell 19.13%, its worst since March 2020, to a new 52-week low. The control makes it clean: Sempra fell only 2-4% on heavier Texas and Mexico exposure and XLU fell about 1%, so this is California statute risk landing on two balance sheets, not a utilities selloff. The detail worth carrying forward is BMO's: it left PG&E's adjusted EPS estimates completely unchanged at $1.65, $1.82 and $1.98 for 2026-2028 while raising its liability drag to $10 per share from $6, with a scenario range of $3 to $35. A fifth of the equity moved on a tail-risk assumption with the operating outlook untouched.

Invalidation For anyone reading this as a long: the legislative status is itself source-conflicted, with one source saying SB 492 officially passed and another saying the compromise has not been voted on yet. Until that resolves, the event may not be over. For anyone reading it as a short: both names rebounded on Sep 1 (+7.17% and +4.82% intraday) and retail sentiment stayed 'extremely bullish' on PCG through the crash, so the dip-buying bid is real.

Risk Edison's Southern California Edison faces the Eaton Fire with sell-side gross potential liability estimated near $13.5B before recoveries against a roughly $20.8B market value, and 30,000 claims in litigation. PG&E already sits one notch below investment grade. These are the two names in the artifact where a genuinely adverse outcome is solvency-relevant rather than valuation-relevant.

SLBVRTneutral · track B

Rationale Recorded because the most strategically consequential corporate action of the window cuts directly against a position this book holds, and that should be stated rather than absorbed quietly into a sub-score. On Aug 31 SLB agreed to acquire Kelvion for roughly $3.4B cash plus $0.7B assumed debt - about $4.1B enterprise value - explicitly to build data-centre thermal management scale. Kelvion's data-centre revenue alone is guided to $1.2-1.3B for 2026, and combined SLB/Kelvion data-centre revenue above $2.0B pro forma at roughly $300M adjusted EBITDA, struck at about 11x pre-synergy EBITDA with $120M of expected annual synergies and accretion to EPS and free cash flow within twelve months. Management's framing was explicit: the deal more than doubles SLB's revenue opportunity per gigawatt of delivered capacity. Vertiv has been held on this book as a pure play on exactly that bottleneck, with 'competitive entry from Schneider and Eaton' listed as a generic risk for several runs. That risk is now a specific, priced transaction by a company with global industrial scale and a stated ambition to become an industrial technology partner to the data-centre industry. VRT's structural sub-score is cut four points and it falls to last on the upside book.

Invalidation For the VRT position: if Vertiv's next print shows content-per-rack or backlog growth that is plainly unaffected, the entry argument was overweighted and the structural leg should be restored. For any SLB consideration: the deal has not closed and is subject to regulatory approval; execution risk on a $4.1B cross-industry integration is real, and SLB's core business remains levered to a crude price that just moved 5.2% in a session on a shooting war.

Risk The uncomfortable reading is broader than one position. A bottleneck that attracts a $4.1B entry from outside the industry is a bottleneck the market has finished discovering, and several Track B upside theses - VRT, GEV, and to a degree AVGO - rest on bottlenecks staying scarce.

Methodology & limitations

THE DEFINING PROBLEM OF THIS RUN: MAGNITUDE BASIS, not source availability. This window produced abundant narrative and very few confirmed close-basis percentage moves. Two post-close recaps between them name roughly a dozen single stocks with percentages; beyond those, the only systematic mover data was a ChartMill screen whose own headline states it was captured ONE HOUR BEFORE the close. Eleven ranked candidates were held out rather than published on an intraday label, and five ranked entries carry a magnitude_intraday flag. Every move_pct field should be read together with its entry's flags. This generalises the week-to-date failure mode documented on 2026-08-28 into a standing rule: establish the BASIS of every percentage before using it - close, intraday, premarket, after-hours or week-to-date.
CHARTMILL'S PERCENTAGE LABELS ARE PARTIALLY UNRELIABLE and the failure is not uniform, which makes it harder to handle than a wholesale discard. Cross-checked against confirmed closes, its PANW figure reconciles EXACTLY (358.97 at -6.06% implies an Aug 31 close of $382.14, consistent with the confirmed Sep 1 close of $362.08 at -5.25%), and its CRWD figure is close. But its Sep 1 AXON label of -1.60% cannot be reconciled with either the Motley Fool's close-basis -8.52% or 24/7 Wall St.'s independent 'more than 6.5%' characterisation, and its own Aug 31 and Sep 1 AXON prices are internally inconsistent with that label. The source is therefore used ONLY where a second source independently names the stock as a session mover, and never as a sole basis for a ranked magnitude.
STOCKMARKETWATCH.COM DISCARDED WHOLESALE FOR THE SECOND CONSECUTIVE RUN. Its live page, crawled during this build, described the Sep 1 session as 'resilient but cautious' with major indexes 'largely flat but leaned toward the positive side' and 'showing marginal gains' - QQQ +0.03%, DIA +0.03%, SPY +0.02%, IWM +0.04% - against confirmed closes of S&P -0.71%, Nasdaq -1.03%, Dow -0.79% and Russell 2000 -1.23%. A twice-documented failure mode; the source is treated as unusable. One consequence: its claim that Salesforce reports on Sep 2 is not carried and is almost certainly wrong given the Aug 27 print.
24/7 WALL ST.'S S&P 500 LEVEL FOR SEP 1 IS AN OUTLIER AND IS NOT USED. It gives 7,659.79 at 'roughly -0.35%' against a three-source close-basis consensus of 7,631.47 at -0.71% (CNBC, Motley Fool, Alain Guillot, with Investrade's -54.56 points reconciling exactly). Its Dow (-0.84%) and Nasdaq (-1.02%) figures are close to confirmed, so the discrepancy appears isolated to the S&P and consistent with a pre-close capture. The publisher's single-stock characterisations are used; its index level is not.
NO CONFIRMED VIX CLOSE FOR EITHER SESSION. The 15.88 figure is an INTRADAY board reading captured 09:50 ET on Sep 1, and the Aug 31 close of 14.92 is derived from it arithmetically rather than sourced. Both are flagged in vix_basis. In a window defined by a war escalation and a bond selloff, not having a settled volatility close is a meaningful gap.
THE RUSSELL 2000 AUG 31 CLOSE IS DERIVED, NOT SOURCED. TheStreet's Sep 1 board showed 2,932.70 at -23.75 points, implying 2,956.45 for Aug 31; Investrade's Sep 1 close-basis decline of -36.32 to 2,920.13 then reconciles exactly against that derived base. The chain is arithmetically sound and is disclosed as a derivation rather than presented as a source.
THE TWO MOST CONSEQUENTIAL EVENTS ADJACENT TO THIS WINDOW FALL OUTSIDE IT, by construction of a pre-market run date. Palo Alto reported after the Sep 1 close and Broadcom reports after the Sep 2 close. The PANW earnings RESULT is recorded as Tier-1 fact and used to resolve the fundamental half of a registered condition; the market's VERDICT on it is not in this artifact and is not scored. After-hours prints (+6% initially, fading to about -2%) are recorded as narrative and explicitly excluded from every sub-score.
PRIOR-RUN PROVENANCE. The 2026-08-31 artifact adopted as this run's anchor was found in the build container rather than retrieved through conversation search, which returned 2026-08-28 as the most recent run. It was verified on three independent axes before adoption - index closes, Track B membership, and both of its substantive sub-score drivers - and one correction was applied (the Nevada robotaxi approval is dated Aug 20, not Aug 31). The full check is recorded in prior_run_provenance. A reader who rejects that artifact entirely should note that Track B MEMBERSHIP is identical under either anchor; only the sub-score baseline and the TSLA and VRT deltas would change.
NO LIVE OPTIONS TAPE. Every options figure is a Market Rebellion broker-desk snapshot, published either pre-market (reflecting the prior close) or mid-session (intraday, non-final). Barchart Unusual Options Activity and Market Chameleon render client-side and return page chrome only, as in every prior run. No post-print vol/OI table was retrievable for any name in this window.
NO BID/ASK SIDE TAGGING on any free source. Every call:put figure is a VOLUME or OPEN-INTEREST ratio. This window produced a direct demonstration of why that matters: into the same Sep 1 close, the PANW book flipped toward puts and the DELL book flipped toward calls, both on rising implied volatility, and both stocks fell. Those outcomes are consistent with the crowd being wrong AND with systematic premium selling; the data cannot distinguish them.
THE OPTIONS RECORD AND THE PRICE RECORD BARELY OVERLAP THIS WINDOW. The Market Rebellion unusual-activity lists are dominated by California utilities, small caps and persistent retail vehicles, while the index damage landed in AXON, the software cohort and the rate-sensitive complex - most of which produced no name-level options data at all. Five of fifteen ranked Track A entries carry an options sub-score of neutral 50 marked UNVERIFIED. The energy complex, which drove the window and produced a $4.1B acquisition, generated literally zero free-tier options coverage.
NO CBOE PUT/CALL RATIO obtained for either session; the official daily statistics page has returned navigation-only content across multiple runs. No index-level hedging read is claimed.
CALIFORNIA SB 492'S LEGISLATIVE STATUS IS UNRESOLVED ACROSS SOURCES - one states the bill officially passed, another dated Sep 1 states the compromise has not been voted on yet. This is not a rounding difference: it determines whether the EIX and PCG repricing is final or whether an unscheduled binary remains. Both readings are recorded and neither is adopted.
UNRESOLVED SOURCE CONFLICTS, published as flags rather than point-estimated: AXON Sep 1 (-8.52% close-basis versus -1.60% intraday versus 'more than 6.5%' characterised - irreconcilable, close-basis used); MRNA Sep 1 (+9.93% close versus +7.05% intraday versus 'gained 5%' midday - consistent with a stock climbing through the session, close-basis used); PANW Sep 1 (-5.25% and -5.24% from two post-close sources, -5.8% from a broker page, -6.06% intraday); ORCL Sep 1 (-5.83% intraday versus 'around 5%' - both soft); EIX Aug 31 (-23.07% close versus -23% midday versus 'as much as 24%' versus -19.5% premarket); PCG Aug 31 (-19.13% and -19.04% within a single source, -18% midday, 'about 20%' elsewhere); Dow Sep 1 (-419.02 per CNBC versus -418.31 per Investrade); the 10-year (4.75% close-basis versus 4.77% and 4.80% from intraday widgets).
TRACK B INFORMATION HOLES INHERITED FROM THE JULY-AUGUST GAP REMAIN OPEN FOR A THIRD CONSECUTIVE RUN and now carry explicit run counts: the LLY and NVO Q2 prints (Aug 5), the AMD Q2 print (Aug 4), and the MRK KEYTRUDA QLEX PDUFA decision (Aug 17). Four positions - two ranked in the top three of their respective books - are scored on theses whose most recent decisive event this pipeline has never read. Sub-scores were NOT moved on unread events; the deltas say 'unchanged, and here is why not'. But three runs is where this stops being a caveat and becomes a research failure, and the MRK trade idea now carries a retire-for-lack-of-evidence clause because of it.
NO CRWV PRICE PRINT WAS OBTAINED FOR EITHER SESSION, the specific reason the CoreWeave watch condition was hardened rather than resolved in either direction. The macro mechanism the thesis names moved sharply in its favour and this pipeline cannot confirm the stock responded.
SCORES ARE HEURISTIC AND NOT BACKTESTED. Sub-scores are analyst judgment applied to cited evidence, not a fitted model. Track A options sub-scores rest on pre-event implied-volatility snapshots and unranked activity lists, which measure expectation and crowding - not realised institutional flow.
BLOCKED OR UNAVAILABLE SOURCES: Bloomberg and CNBC return 403 to automated fetch (content here comes via search index); Seeking Alpha is robots-disallowed and only headline summaries were accessible; CappNotes Closing Look was not indexed for either session, removing this pipeline's most reliable single close-basis recap source for a second consecutive run; the Market Rebellion September 1 reports required search-based retrieval after a permissions error on direct fetch, the standing pattern for this source.

Not financial advice. Educational/analytical only — generated by Daily Market Pulse template v1 - multi-desk research run (regime handoff from earnings to oil and rates, Track A movers across two sessions under an explicit magnitude-basis discipline, California statutory repricing, the SLB/Kelvion transaction and its Track B consequence, options positioning and crowding, forward catalysts through Sep 9, Track B conviction review with a formal pre-registered condition ledger and a verified prior-run provenance check), synthesized 2026-09-02 pre-market. Do your own diligence.

Market Pulse Overview for Aug 31, 2026